{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:35:43Z","timestamp":1649194543726},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1509,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1111\/j.1600-0609.2011.01628.x","type":"journal-article","created":{"date-parts":[[2011,7,15]],"date-time":"2011-07-15T13:40:55Z","timestamp":1310737255000},"page":"182-185","source":"Crossref","is-referenced-by-count":1,"title":["Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation"],"prefix":"10.1111","volume":"87","author":[{"given":"Vanesa","family":"Mart\u00edn-Palanco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Arqueros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Rom\u00e1n-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,15]]},"reference":[{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11912-010-0116-1","article-title":"Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the \u201cbest\u201d therapy?","volume":"12","author":"Agrawal","year":"2010","journal-title":"Curr Oncol Rep"},{"issue":"Suppl 1","key":"10.1111\/j.1600-0609.2011.01628.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/bmt.2008.105","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007","volume":"42","author":"Goldman","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","article-title":"Role of donor lymphocyte infusions in relapsed haematological malignancies after stem cell transplantation revisited","volume":"36","author":"Deol","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2009.08.019","article-title":"Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML)","volume":"16","author":"Klyuchnikov","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood.V100.5.1590.h81702001590_1590_1595","article-title":"Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia","volume":"100","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1158\/1078-0432.CCR-03-0580","article-title":"Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease","volume":"10","author":"DeAngelo","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1200\/JCO.2005.01.3110","article-title":"Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study","volume":"23","author":"Hess","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3324\/haematol.13353","article-title":"Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation","volume":"94","author":"Hayat","year":"2009","journal-title":"Haematologica"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCRABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.leu.2403622","article-title":"Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion\/deletion polymorphisms","volume":"19","author":"Jim\u00e9nez-Velasco","year":"2005","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01628.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u2003years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01628.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2011.01628.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T05:29:02Z","timestamp":1625635742000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01628.x"}},"subtitle":["Letter to the Editor"],"short-title":[],"issued":{"date-parts":[[2011,7,15]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01628.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,15]]}}}